SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
Biogen
An SI Board Since August 1996
Posts SubjectMarks Bans Symbol
1686 75 0 BIIB
Emcee:  Harold Engstrom Type:  Unmoderated
Introduction Market Data Compact
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
1536Wachovia: BGEN: Strong Q3 2003 Results--Raising 2004 Estimates: Reiterate Markemopgcw-10/29/2003
1535GS: Biogen, Inc. EPS (FY Dec) 2003E $1.80, 2004E $2.08 Not Rated/Neutral (BGEN) mopgcw-10/28/2003
1534Biogen's Psoriasis Drug Helps Treat Arthritis, Report Finds By LAURA JOHANNmopgcw-10/26/2003
1533Antibodies Reduce Interferons' Effect Against MS, Lancet Says Oct. 10 mopgcw-10/9/2003
1532GS: Biogen, Inc. EPS (FY Dec) 2003E $1.80, 2004E $2.08 Not Rated/Neutral (BGEN) mopgcw-10/6/2003
1531New Study Shows Long-Term Effect of AVONEX(R) on MS Monday, September 22, 200mopgcw-9/22/2003
1530BGEN was up 5.76% for the week ending 8-29-03. Biotech stocks in general closed blackmerlin-8/30/2003
1529From Alan Abelson's column in Barrons, re IDPH & BGEN: #reply-19125905Doc Bones-7/19/2003
1528Mark, your link ain't too useful.John William Anderson-6/23/2003
1527Biogen and Idec to merge: online.wsj.comMark Bong-6/23/2003
1526Amgen Inc. EPS (FY Dec) 2003E US$1.84, 2004E US$2.22 Outperform/Neutral (AMGN) Umopgcw-6/19/2003
1525GS report: Stock rating: Outperform Coverage view: Neutral Mid-Cap Growth Pricmopgcw-6/13/2003
1524SSB report: BGEN: Ends Collaboration with ICOS on Psoriasis Drug mopgcw-6/13/2003
1523CAMBRIDGE, Mass., June 13 /PRNewswire-FirstCall/ -- Biogen, Inc. (Nasdaq: BGEN -nigel bates-6/13/2003
1522BAYER TO MARKET GW'S CANNABIS-BASED MEDICINE GW Pharmaceuticals, which has pHarold Engstrom-5/21/2003
1521could antegren be the answer ? if its as good as i hear then rebiff is gonna bedalroi-5/19/2003
1520Anemic at Biogen <i>These "Business Week - INSIDE WALL STREET" Doc Bones-5/16/2003
1519The Goldman Sachs Biotechnology Team will host a Conference Call on Thursday, Apmopgcw-4/10/2003
1518SSB's take: Biogen, Inc. (BGEN) BGEN: Earnings Upside Driven by Reduced mopgcw-4/4/2003
1517Dang, I knew sub-$30 was a buy, but hesitation... Biogen Announces Improved Permopgcw-4/2/2003
1516GS on recent Psoriasis Meeting: At a dermatology meeting biological agents weremopgcw-3/25/2003
1515From Morningstar: The delay of European marketing approval for Biogen's BGEmopgcw-2/21/2003
1514Europe regulators reject Biogen drug Amevive may not hit that market till 2005 Icebrg-2/21/2003
1513European Approval of AMEVIVE(R) Delayed Thursday February 20, 8:11 am ET Commimopgcw-2/20/2003
1512Biogen developed Bivalrudin as a direct thrombin inhibitor. The product rights Mike-2/19/2003
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News